See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Ukraine War
Volodymyr Zelenskyy
Pope Francis
Donald Trump
Vladimir Putin
Elon Musk
US Politics
CPAC
Basketball
Vatican
Wrestling
Baseball
Published • loading... • Updated

Efficacy and Safety of Elinzanetant for Menopausal Vasomotor Symptoms: Results from OASIS 1 and 2 Trials

Summary by healtheconomics.com
The OASIS 1 and 2 randomized clinical trials evaluated the efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist, in postmenopausal individuals experiencing moderate to severe vasomotor symptoms (VMS). Conducted across multiple sites in the US, Europe, Canada, and Israel, these phase 3 trials involved postmenopausal participants aged 40 to 65 years. Participants received either 120 mg of elinzanetant daily for 26 we…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
healtheconomics.comhealtheconomics.com

Efficacy and Safety of Elinzanetant for Menopausal Vasomotor Symptoms: Results from OASIS 1 and 2 Trials

The OASIS 1 and 2 randomized clinical trials evaluated the efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist, in postmenopausal individuals experiencing moderate to severe vasomotor symptoms (VMS). Conducted across multiple sites in the US, Europe, Canada, and Israel, these phase 3 trials involved postmenopausal participants aged 40 to 65 years. Participants received either 120 mg of elinzanetant daily for 26 we…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

healtheconomics.com broke the news in on Friday, January 31, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
Search
BlindspotLocal